{
    "nctId": "NCT00320541",
    "briefTitle": "A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer",
    "officialTitle": "A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 187,
    "primaryOutcomeMeasure": "Overall Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females diagnosed with breast cancer and the cancer has spread to distant areas of the breast or organs.\n* Must be able to measure the disease by specific medical parameters\n* May have received breast cancer treatment in the early stage of the disease\n* May be restricted in physically strenuous activity but able to carry out light work.\n* Must have adequate organ function as seen in blood test results.\n\nExclusion\n\nCriteria:\n\n* Cancer that has spread to the brain.\n* Unstable heart problems\n* Unstable high blood pressure.\n* Breast cancer treatment after the disease has considered to spread to other areas or organs.\n* Unable to agree with the requirements of the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}